New Climate Strategy
BeiGene will set a quantitative Scope 1 and 2 emissions goal by 2024 and plans to set a quantitative Scope 3 emissions goal by 2025. In 2022, we are building a strategic roadmap that includes energy efficiency projects and renewable energy purchases. We will begin conducting energy audits in our R&D and manufacturing facilities, which account for the majority of our Scope 1 and 2 emissions. We are also assessing how to best reduce GHG emissions across our value chain.
Our ability to rapidly develop and commercialize new medicines is helping us bring innovative, life-saving medicines to millions more patients globally. To meet the growing demand for our medicines, we are investing in additional laboratory space and manufacturing capacity, resulting in increased GHG emissions, water use, and waste creation. While our overall resource use is projected to increase, we are working to improve our efficiency, producing more product with fewer inputs per batch.
- Set a quantitative Scopes 1 and 2 emissions goal by 2024
- Set a quantitative Scope 3 target by 2025. To advance this goal, we will engage with two-thirds of our raw material supplier base (using 2021 spend information)